Treatment Practices for Extended-Stage Small Cell Lung Cancer
Medical oncologists provide comprehensive insights on treatment practices for patients with extended-stage small cell lung cancer.
Incorporating PCI Following ADRIATIC Study
Following recent data from the ADRIATIC study, the Oncology Brothers and Eric Singhi, MD, discuss the role of prophylactic cranial irradiation (PCI) in patients with small cell lung cancer.
Treatment Algorithm for Limited-Stage Small Cell Lung Cancer
Eric Singhi, MD, joins the Oncology Brothers, Rahul Gosain, MD, and Rohit Gosain, MD, to discuss the treatment algorithm for patients with limited-stage small cell lung cancer (SCLC), highlighting the ADRIATIC study.
Key Findings from the INTERCEPT Study
GI medical oncologists review recent findings from the INTERCEPT study evaluating the prognostic performance of circulating tumor DNA in clinical practice.
The Role of ctDNA as a Biomarker in Colorectal Cancer
Stacey A. Cohen, MD, and Daniel H. Ahn, DO, discuss the role of circulating tumor DNA (ctDNA) as a biomarker in colorectal cancer and provide clinical insights on screening modalities.
Naval Daver, MD on Phase 1/2 Trial of DSP-5336 in R/R Acute Leukemia
A phase 1/2 trial assessed the use of menin inhibitor DSP-5336 in patients with acute leukemia overexpressing HOXA9 and MEIS1.
Tanya B. Dorff, MD, on Phase 1 Trial of CAR T-Cell Therapy in mCRPC
A phase 1 trial assessed the use of PSCA-directed CAR T cells in patients with metastatic castration-resistant prostate cancer.
Acalabrutinib Appears More Effective in Earlier Lines of Treatment for CLL
A pooled analysis trial assessed the impact of acalabrutinib in patients with chronic lymphocytic leukemia across treatment lines.
Adverse Event Considerations for DARA-VRd in NDMM
Experts on multiple myeloma discuss the safety profile of DARA-VRd in patients with newly diagnosed multiple myeloma.
Long-Term Follow-up with Teclistamab in R/R MM: Updates from MajesTEC-1
Samer Al'Hadidi, MD, provides an overview of recent updates presented at ASCO 2024 from the MajesTEC-1 trial evaluating teclistamab in patients with relapsed/refractory multiple myeloma.
Key Efficacy Data from PERSEUS in Newly Diagnosed Multiple Myeloma
Myeloma specialists provide comprehensive insights on key data from the PERSEUS trial evaluating MRD status in patients receiving DARA-VRd and VRd.
Updates From the Phase 2 MonumenTAL-2 Study Investigating Talquetamab in R/R MM
Hans Lee, MD, discusses recent updates from the MonumenTAL-2 study investigating talquetamab in patients with relapsed/refractory multiple myeloma.
Unmet Needs and Key Takeaways: ECHO Clinical Trial
Medical experts evaluate unmet needs, key insights from the Phase 3 ECHO trial, and potential obstacles in integrating the findings into existing treatment protocols.
Phase 3 ECHO: Safety Data Review
Medical experts analyze and provide insights on safety findings from the Phase 3 ECHO trial, offering their professional interpretations of the data.
Describing the Value of ctDNA in Clinical Practice
The key opinion leaders share their approaches for communicating about circulating tumor DNA and minimal residual disease to patients, emphasizing the significance of ctDNA testing in detecting MRD.
Circulating Tumor DNA Detection Techniques
Experts outline circulating tumor (ct) DNA analysis, detailing the two main techniques and their respective advantages and disadvantages.
Tanya B. Dorff, MD, on Results From Phase 1 CAR T-Cell Therapy mCRPC Trial
Findings from a phase 1 study may inform future trial designs intended to yield longer responses with PSCA-targeted CAR T cells.
Improving Access for Patients Receiving CAR T-Cell Therapy
Experts on multiple myeloma provide clinical insights on unmet needs associated with CAR T-cell therapy, focusing on patient access across academic and community settings.
Educating Patients on Complications Associated with CAR T-Cell Therapy
The panel provides clinical insights on talking with patients about complications associated with CAR T-cell therapy.
Assessing the Benefit of CAR T-cell Therapies for mCRPC
.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "Cesar Rodriguez, MD, and Frits van Rhee, MD, PhD")
.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "This series features 2 KOLs.")
.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "4 KOLs are featured in this panel.")
